In the world of life sciences, we’re standing at the edge of a transformative era. The last decade has seen machine learning carve out significant advancements, enabling experts to predict protein interactions and design molecules with unprecedented precision. 

Causaly cofounders Yiannis Kiachopoulos and Artur Saudabayev hosted a webinar, “From AI to Impact”, in April 2023, exploring the transformative power of AI and GPT applications in early drug discovery. During this captivating session, they demonstrated how Causaly combines visual evidence with high precision knowledge graphs to answer complex research questions in mechanistic biology.   

At Causaly, we stay close to the developments in the foundational natural language processing technologies and broader AI to understand where we stand with both academic and industrial state-of-the-art.

It is widely recognized that the Scientific Method is fundamental for discovering new medicines. We’re all familiar with the process: a researcher poses a question, such as what causes a specific disease, then gathers all relevant information that is known about their question. Upon digesting this information, they formulate a hypothesis and design experiments to […]

Causaly and Autobahn Labs – an early stage drug discovery incubator launched by Evotec, Samsara Biocapital and KCK – co-hosted a joint webinar on the 29th of June